This rationale has been used to explain why
Regardless of the validity - or not - of this position, such public statements are, in the current situation, likely to further destabilise an already highly uncertain market.
The reality is that semi-synthetic artemisinin is simply another source of a compound already used in malarial therapies. Sufficient global supplies can be produced by farmers and, in fact, this year a surplus of plant-derived artemisinin is expected.
Since the new form is not cheaper than the existing source, nor alleviating a shortage, it will - at best - play a relatively small part among the multitude of factors that determine whether or not people suffer and die from malaria.
For example, the local price of ACTs is largely determined by donor strategies rather than the price pharmaceutical companies charge.
When I have put such considerations to scientists and others who glorify the project, they have argued that these are outside their remit and sphere of expertise.
Fair enough, perhaps. But if they do not want to take responsibility for the real-world complexities of what happens beyond the confines of the laboratory, they should take care not to make simplistic claims about the project's global health benefits.
I do not wish to dispute the humanitarian motivation of those involved. But synthetic biologists and their supporters have latched on to this project because they believe they need a success story to demonstrate the societal benefits of the field in order to counter what they perceive - wrongly - as the public's general opposition to genetic modification (GM). 
This fails to recognise that the current controversy around GM crops developed partly as a result of similar, overblown promises, made in the late 1990s, about their prospects for 'feeding the poor' that proved out of step with what was actually delivered.
Far from helping to promote the field, the use of the
Some of the first synthetic biology products on the market are cosmetics containing compounds produced by the companies
 Sanders, R. Launch of antimalarial drug a triumph for
 Speech by the Chancellor of the Exchequer, Rt Hon George Osborne MP, to the
 Peplow, M. Malaria drug made in yeast causes market ferment (Nature,
 Thomas, J. Synthetic anti-malarial compound is bad news for artemisia farmers (The Guardian, 2013)
 Dransfield, S. Put an end to risky malaria scheme, warns
 EMBO Reports 2 (7), 545 (2001)
Most Popular Stories
- 15 Myths That Could Ruin Your Hispanic Ad Campaign
- Bitcoin Clones Lurch Onto Financial Scene
- General Motors Names Mary Barra as First Female CEO
- Clinton to Keynote Annual Simmons Leadership Conference
- AIG to Create 230 Jobs in Charlotte
- How Bitcoin and Other Cryptocurrencies Work
- Californians Want to Legalize Marijuana
- Selena Gomez, Shakira Among Top Hispanic Searches
- Pacific Trade Pact Delay Hinders U.S. Pivot to Asia
- PhD Project Grooms Business Profs